Uganda’s Mandatory Newborn Sickle Cell Disease Screening Programme: Translating a Decade of Evidence into Differentiated Implementation Authors: Bwambale Jonani, Betty Nakawuka, Enock Ssebunya, Richard Kwizera, Felix Bongomin, Gerald Mboowa Published: 2026 ABSTRACT AbstractUganda’s sickle cell disease (SCD) prevalence of 1.3% and sickle cell trait (SCT) prevalence of 13.3% nationally represent a substantial public health burden, with an estimated 20,000 affected infants born annually. On 9 February 2026, Uganda’s Ministry of Health launched a nationwide mandatory newborn screening programme for SCD, placing the country among the first in sub-Saharan Africa to implement universal birth screening. This policy builds on over a decade of evidence, including the Uganda Sickle Surveillance Study, and cost-effectiveness analyses showing dried blood spot (DBS) screening costs of $5.88 per child, with viable point-of-care thresholds of $3.07–$5.09. However, the initial rollout relies on rapid diagnostic tests within existing hub-and-CPHL systems and does not yet fully cover private facility births, immunization-based catch-up for missed cases, or older unscreened children. In addition, the current 4–6-week turnaround time with centralized confirmation at Central Public Health Laboratories remains an operational limitation. We propose a differentiated implementation framework to strengthen the programme. It aligns screening strategies with care entry points and age-specific test performance. Private facilities would use a microchip electrophoresis analyzer (Gazelle™) at birth due to reduced accuracy of lateral flow tests in high fetal hemoglobin. Public facilities would integrate Sickle SCAN or HemoTypeSC into immunization contacts from six weeks of age, with the 9-month contact prioritized as the most reliable screening timepoint given the progressive decline in HbF, and school-based programmes would target children aged 1–5 years who were previously missed. All pathways would connect to Uganda’s 100-laboratory hub network for electrophoretic confirmation, potentially reducing turnaround time to 48–72 hours. By leveraging existing delivery, immunization, and laboratory infrastructure, this framework offers a feasible and equitable route to translate Uganda’s mandatory screening policy into large-scale health impact. Introduction On 9th February 2026, the Ministry of Health Uganda launched a nationalwide mandatory newborn screening program for Sickle cell disease (SCD), making Uganda one of the first countries in sub-Saharan Africa to commit to population-level screening.1 Screening is being conducted using rapid diagnostic tests (RDTs) at all government-run health facilities before mothers are discharged, with the National Medical Stores supplying the RDT kits free of charge to the facilities.1 This milestone reflects more than a decade of systematic evidence building, from the Uganda Sickle Surveillance study (US3)2 through targeted screening pilots, cost-effectiveness analyses,3 and participation in the Consortium on Newborn Screening in Africa (CONSA).4 This launch represented a turning point in Uganda’s response to one of its most prevalent genetic disorders, yet the launch itself was only the beginning. The program currently operates within the existing hub-and-spoke laboratory network relying on the Central Public Health Laboratories (CPHL), a system that, while functional, carries a 4–6 week turnaround time that has previously shown to be a critical barrier to care linkage.5 Equally important, mandatory screening at delivery does not yet address children who are missed at birth, those presenting through immunization contacts in the first year of life, or the larger cohort of older unscreened children. How Uganda operationalizes this commitment across public and private facilities through immunization platforms, and into school-age catch-up, will determine whether mandatory screening translates into lives saved at scale. The burden justifying this commitment is substantial. Approximately 515,000 infants with SCD are born globally each year, with over 79% in sub-Saharan Africa.6 SCD has recently been identified as the leading contributor to mortality among children aged 5–14 years globally.6 In Uganda, an estimated 20,000 babies are born with SCD annually, with approximately 80% dying before an age of five if undiagnosed and untreated.1 The US3 study demonstrated a sickle cell trait (SCT) prevalence of 13.3% and SCD prevalence of 1.3% nationally,2 figures subsequently confirmed across 112,353 samples during the Ministry of Health 2015–2018 targeted screening program.7 The evidence for early intervention is unequivocal. A landmark California study following 85 children with SCD over 7.2 years demonstrated a mortality rate of only 1.8% when newborn screening enabled early intervention,8 a stark contrast to outcomes in settings where the majority of affected children remain undiagnosed until severe complications arise. The question facing Uganda’s health system is therefore no longer whether to screen, but how to screen effectively, equitably, and sustainably within real infrastructure and budget constraints. We present an evidence-informed implementation framework to complement Uganda’s universal NBS program, drawing on ten years of Ugandan data to address the critical operational questions: which point of care (POC) technology is appropriate for which healthcare setting and age group, how can screening costs be financed without creating access barriers in private facilities, how can the existing 100-laboratory hub network9 reduce turnaround time, and how can results reach families quickly enough to enable timely intervention. The framework is pragmatic rather than perfect, designed to leverage existing infrastructure including the Uganda National Expanded Program on Immunization (UNEPI) and the Joint Medical Stores (JMS) supply chain, while remaining cognizant of the cost constraints, technology limitations, and equity challenges that any differentiated implementation approach must navigate. Uganda’s Approach to Building Evidence Base Between 2014 and 2026, Uganda has systematically built the evidence base that ultimately drove the February 2026 policy decision to mandate universal newborn screening. This evidence base rests on three pillars: disease quantification, cost-effectiveness analysis, and technological evaluation. Disease Burden Early evidence of Uganda’s SCD burden predates the US3 study. Serjeant and Ndugwa documented the clinical features and mortality patterns of SCD in Uganda as early as 2003, making an early call for urgent national action.10 The Uganda Sickle Surveillance Study (US3, 2014–2015) subsequently generated the first rigorous national prevalence data, showing a 13.3% prevalence of sickle cell trait among children aged 0–18 months, with 0.6–0.8% prevalence of SCD.2 Similar rates were observed across HIV-positive (0.5%) and HIV-Negative (0.8%) infants, underscoring the need to screen all newborns rather than restricting testing to HIV-exposed infants. The Ministry of Health responded with a three-year targeted screening project (March 2015–April 2018) that confirmed the substantial national burden of SCT and SCD. Across 112,353 samples from all regions of the country, SCT prevalence was 15.5% and SCD prevalence reached 1.3%, nearly double the levels observed during the earlier one-year pilot.7 This geographic overview established SCD as a national problem requiring population-level intervention. The programme utilized dried blood spot (DBS) samples collected at health facilities and transported through the existing hub system to CPHL for testing using Isoelectric focusing (IEF). While operationally feasible, a 4–6 week Turn Around Time (TAT) emerged as a critical barrier to care linkage, with many families unreachable by the time results were available.5 By 2021, Uganda had joined the Consortium on Newborn Screening in Africa (CONSA), connecting to standardized protocols and collaborative learning across seven African countries.4 This cumulative evidence, a decade in the making, formed the scientific foundation for the February 2026 mandatory screening launch, which now operates through the same hub-and-CPHL infrastructure, making TAT reduction and decentralized confirmation the programme’s most pressing operational challenge. Economic Realities Uganda’s cost effectiveness study, which evaluated the existing DBS-based program at CPHL, revealed a total cost of $5.88 per child screened ($1.74 facility collection plus $4.14 laboratory processing at CPHL).3 Of this total, $3.67 represented direct financial costs, with the reminder comprising donated time and resources. This analysis further revealed that for POC testing to be cost-competitive when considering direct financial costs alone, tests would need to be priced between $3.07 and $3.51 per test depending on the specificity. When all economic costs, including donated time and resources, were considered, the threshold ranged from $4.38 to $5.09.3 These Uganda-specific thresholds are particularly valuable because they are grounded in the actual programmes costs rather than theoretical models adopted from other settings, giving decision makers a defensible price ceiling for procurement negotiations. The findings also highlighted a dimension that unit cost alone does not capture. POC testing becomes increasingly attractive when the full cost of current system is properly accounted for, including transportation of DBS samples, the extended 4–6 week TAT, and the cost of failed care linkage when families cannot be traced by the time results are available. The February 2026 mandatory launch has made these economic considerations more urgent, as the programme now needs to demonstrate not only that screening is affordable but that it is operationally efficient enough to connect diagnosed infants to treatment within a clinically meaningful timeframe. The Technology Landscapes Three POC technologies are relevant to Uganda’s NBS context: Sickle SCAN, HemoTypeSC and the microchip electrophoresis analyzer. Each operates on a different detection principle, and it is that difference in mechanism, not differences in brand performance, that determines which technology is appropriate for which setting and age group. Understanding how each works, not just how well it performs, is essential to matching technology to setting, because the detection mechanisms determines both where a test excels and where it fails. Sickle SCAN is a lateral flow immunoassay that detects HbA, HbS, and HbC through specific antibody recognition.11 It does not measure or detect HbF. In older infants and children where HbS constitutes a substantial proportion of total hemoglobin in infected individuals, Sickle SCAN has demonstrated diagnostic accuracy of up to 99% in both laboratory and field settings.12 Its simplicity, speed, and low infrastructure requirements make it well suited to high-volume community settings such as immunization clinics and school outreach programmes. However, in the immediate newborn period, fetal hemoglobin constitutes 50–90% of the total hemoglobin.13,14 HbF declines rapidly postnatally, reaching near-adult levels by 16–20 weeks of age.15,16 Because Sickle SCAN detects HbS through antibody binding rather than physical separation, the relative dilution of HbS by dominant HbF can reduce the HbS signal below detection threshold in HbSS newborns, creating a risk of false negative results. This limitation is not unique to Sickle SCAN. It applies to all lateral flow immunoassays used at or near the time of birth. It does not, however, preclude their use in the newborn period. Current practice at CONSA sites supports the use of lateral flow immunoassays from birth, mitigating this risk through a structured safety net whereby positive results at any age proceed to confirmatory testing by IEF or HPLC, and any infant with a negative result but strong clinical suspicion is retested at a later immunization contact when HbF has further declined. Beyond the neonatal HbF issue, Sickle SCAN does not detect hemoglobin variants beyond HbA, HbS, and HbC, meaning variants such as HbO-Arab, D-Punjab, HbA2 will be missed.17 For Uganda’s programme, where HbSS and HbSC account for the overwhelming burden of clinically significant SCD and HbAS represents the most common carrier state requiring genetic counselling, this limitation is operationally manageable provided confirmatory testing protocols are in place. HemotypeSC is another lateral flow immunoassay that detects HbA, HbS and HbC,18 and shares Sickle SCAN’s core detection mechanism and therefore its core limitation, where high HbF in the immediate newborn period poses the same false negative risk. In older infants and children, HemotypeSC has demonstrated 93.4% sensitivity and 99.9% specificity,17 and feasibility studies integrating it into routine immunization clinics have shown 100% concordance with High Performance Liquid Chromatography (HPLC),19 evidence that supports its use at immunization contacts with confirmatory IEF or HPLC for all positive results and repeat testing where clinical suspicion warrants it. An additional limitation specific to HemotypeSC is that it cannot reliably differentiate homozygous HbSS from HbS/βo-thalassemia, which shares a similar antibody pattern, potentially leading to misclassification in the absence of confirmatory testing.20,21 HemotypeSC is distributed in Uganda and represents a viable alternative to Sickle SCAN in settings where it is available, with comparable performance and similar work flow requirements. The microchip electrophoresis analyzer operates on an entirely different principle from the two lateral flow immunoassays. It is a microchip-based electrophoresis device that physically separates hemoglobin fractions by electrical charge, providing a quantitative detection of HbA, HbS, HbF, HbC, and HbA2/C/E in approximately 8 minutes using 20 µL of whole blood.22 Because the microchip electrophoresis analyzer physically separates hemoglobin fractions rather than relying on antibody thresholds, it can identify HbS even when HbF is the dominant fraction, making it more reliable in the immediate newborn period than lateral flow immunoassays. However, its limitations include reduced accuracy in preterm infants below 37 weeks of gestation, inability to screen for beta thalassemia in infants under six months,23 and the practical constraint that the instrument processes one sample at a time, a workflow consideration relevant to high volume settings. Taken together, these three technologies form a complementary toolkit rather than competing alternatives. No single platform of the three optimally serves all ages and all settings. The clinical need at each entry point determines which technology is appropriate. At delivery, where HbF concentrations are highest and immediate pre-discharge results are required, electrophoretic separation is the technically correct approach and the microchip electrophoresis analyzer is currently the most portable available option meeting this specification. At immunization contacts and school-based outreach, where throughput is high and HbF has partially declined, lateral flow immunoassays including Sickle SCAN and HemoTypeSC offer the speed, simplicity, and cost profile the setting demands. All positive POC results, regardless of technology, require confirmatory testing at the reference laboratory before a definitive diagnosis is communicated to families. Confirmatory testing may be performed by the microchip electrophoresis analyzer, IEF, or HPLC, all of which provide definitive hemoglobin separation and genotype classification. In Uganda’s context, the microchip electrophoresis analyzer is proposed for hub-level confirmation on the basis of its portability, speed, and established field performance, while IEF remains the reference standard at CPHL for complex or ambiguous cases. The inclusion of these devices on the WHO Essential Diagnostics List reflects the principle that widely available tools with known and manageable limitations deliver greater public health benefit than more accurate technologies that remain operationally inaccessible across most of Uganda’s health system.24 A Differentiated Implementation Strategy The February 2026 mandatory screening launch covers newborns at government facilities at discharge but does not yet fully address private facility births, immunization-linked screening in the first year of life, or older unscreened children. The framework presented here is designed to complement the existing launch by providing differentiated implementation pathways for each of these gaps, matched to Uganda’s existing healthcare infrastructure. Uganda’s healthcare system operates through a hierarchical structure serving approximately 46 million people, with 16 regional referral hospitals, 207 general hospitals, 284 Health Center IVs, 2,089 Health Center IIIs, and 3,667 Health Center IIs.25 Critically, the ministry of health has established a network of 100 laboratory hubs strategically positioned to serve facilities within a 40-kilometer radius,9 and originally designed for HIV/TB diagnostic services but directly adaptable for NBS confirmation and quality supervision. Private Facilities Pathway Private and faith-based facilities account for approximately 12.6% of births in Uganda,26 concentrated in urban and peri-urban areas. In these settings, delivery package costs range from $161 to $322 for normal deliveries and $538 to $1,344 for cesarean sections. Sickle cell screening currently adds $14–$21 for the microchip electrophoresis analyzer testing or $5–$8 for Sickle SCAN/HemotypeSC, creating a potential access barrier at an already costly point of care. We propose that private facilities incorporate screening costs into standard delivery package fees, eliminating separate charges that may deter uptake. For the choice of technology at the point of delivery in private facilities, immediate pre-discharge neonatal screening requires a technology whose diagnostic accuracy is not compromised by the high HbF concentrations present at birth. Lateral flow immunoassays, which rely on antibody detection thresholds, carry a false negative risk when HbF dilutes the HbS signal below detectable levels in this period. Electrophoretic separation, which physically resolves hemoglobin fractions by charge regardless of their relative proportions, meets the neonatal requirement. The microchip electrophoresis analyzer is currently the most field-deployable electrophoretic platform available in Uganda and is therefore proposed for this pathway, though any electrophoretic or HPLC-capable platform meeting the same specification would be appropriate. The only challenge with the microchip electrophoresis analyzer would be its one-sample at a time processing speed, which is still manageable in private facilities because their delivery volumes are typically lower than in large public facilities, and where the priority is immediate results before the family is discharged. Results should be communicated to families before discharge, with trained staff providing initial counselling on what the results mean and what follow-up is required. The microchip electrophoresis analyzer results showing ambiguous patterns (HbS present with atypical quantitative fractions, uncertain HbA2/C/E peaks, or suspected compound heterozygotes) should proceed to CPHL for IEF confirmation. The cost of confirmatory testing for ambiguous results in the private sector should be clearly defined in advance, either absorbed by the facility or covered through a government subsidy mechanism, to avoid unexpected costs falling on families. Public Facility Pathway Government facilities deliver the majority 87.4% of Uganda’s births26 and represent the primary scale pathway for universal screening. The February launch has already established mandatory RDT-based screening at discharge in these facilities, with NMS supplying kits free of charge. However, screening at delivery alone leaves critical gaps. Preterm infants or high risk infants may be discharged before confirmatory results are available, and families who deliver at home are entirely missed at this entry point. The immunization platform addresses this gap directly. Uganda’s National Expanded Program on Immunization (UNEPI), established in 1983, operates through a well-developed network extending from national to community level, reaching children at 6, 10, and 14 weeks and again at 9 months.25 With 2,077,644 children under one year of age by 2025, projected to reach 2,259,749 by 2028,25 this infrastructure represents an underutilized platform for catch-up SCD screening of children missed at birth. Lateral flow immunoassay carries an acknowledged HbF-related limitation in the newborn and early infant period, a risk that does not disappear at the 6-week immunization contact but diminishes progressively as HbF declines towards adults levels by 16–20 weeks of age.15,16 Current CONSA practice supports the use of lateral flow immunoassays from birth, mitigating this limitation through two mechanisms rather than restricting the technology by age. First, any infant with a negative lateral flow immunoassay at 6 or 14 weeks where clinical suspicion exists should be retested at the 9-months contact. Second, all positive results regardless of age proceed to hub-level electrophoretic confirmatory testing within 48–72hours, which physically separates hemoglobin fractions and is not confounded by HbF levels. A clinical evaluation of the microchip electrophoresis analyzer in 265 newborns aged 0–3 days demonstrated 96.8% accuracy for hemoglobin variant detection, with strong agreement with high-performance liquid chromatography (HPLC) (Pearson correlation coefficients of 0.93–0.97 for HbA, HbF, HbS, and HbC/E/A2).27 These findings support its suitability for point-of-care newborn screening in low-resource settings. Its electrophoretic separation mechanism physically separates hemoglobin fractions and is therefore not confounded by HbF levels. The primary rationale for confirming all positive results is not an assumption of POC test failure but reflects standard practice across hemoglobin screening programmes globally, where confirmation by a secondary method prior to final diagnostic decision making and treatment initiation is warranted by the clinical gravity of enrolling a child into lifelong sickle cell disease care.28 The 9-month immunization contact, where HbF has fully declined, represents the most reliable lateral flow screening timepoint within the immunization schedule and should be prioritized as the catch-up contact for children not screened at birth. This two-tier approach preserves diagnostic accuracy while dramatically reducing the burden on CPHL by 85–95%. Hub-level microchip electrophoresis analyzer confirmation can definitely classify the overwhelming majority of SCT and SCD cases, with only genuinely ambiguous results (estimated 1–5%) requiring onward referral to CPHL for IEF. This keeps the turnaround time within a clinically actionable window. School-Based Catch-Up Pathway A significant cohort of children will remain unscreened despite delivery-point and immunization-linked efforts, particularly those born at home, those from families who missed immunization contacts, and the large population of older children who predate the programme entirely. School entry represents a practical and high-coverage catch-up entry point, given Uganda’s relatively high primary school enrollment rates.29 School-based screening using Sickle SCAN or HemotypeSC can be integrated into existing school health programmes and implemented by trained health workers during outreach visits, requiring minimal additional infrastructure beyond the test kits and referral pathway. It must be acknowledged that school-based screening targets children aged five and above, an age by which, in Uganda’s context, a substantial proportion of undiagnosed HbSS children will already have died or experienced severe preventable complications. This underscores that the school pathway is a safety net, not a substitute for early newborn and immunization-linked screening. Community-based outreach through VHTs, targeting children in the 9-month to school-entry gap, should be developed as an additional bridge to ensure continuity of coverage across all age groups. Laboratory Hub Network as the Backbone The 100-laboratory hub Network is the structural backbone that makes the differentiated strategy operationally effective. Originally established for HIV and TB diagnostics, each hub serves 20–30 health facilities within a 40-kilometer radius and already operates established sample transport and result reporting systems.9 Positioning an electrophoretic platform, the microchip electrophoresis analyzer, or any HPLC or IEF-capable equivalent, at each hub transforms this existing infrastructure into a two-tier NBS confirmation system. Where hubs already operate HPLC or IEF for other diagnostic purposes, those platforms should be utilized for SCD confirmation rather than procuring additional devices/infrastructure. The hub’s role in this framework is threefold. First, it provides second-line confirmatory testing for all lateral flow positive assays from health centers, immunization sites, and school-based programs within its catchment, targeting a 48–72 hours TAT from receipt. Second, it provides quality supervision for peripheral screening sites through quarterly visits, ensuring test performance and results recording standards are maintained. Third, it serves as the data aggregation point for DHIS2 reporting, tracking screening coverage, positivity rates and loss-to-follow-up within each catchment area. Supporting Infrastructure Antenatal Care Integration Antenatal contacts represent an unutilized opportunity to prepare families for newborn screening. Parental carrier screening during antenatal visits identifies couples at risk of an affected infant, enabling targeted counselling before delivery and improving family readiness to engage with newborn results. Even when parental screening is not performed, antenatal health education about SCD covering what it is, what screening involves, and what a positive result means, reduces anxiety and increases the likelihood that families will engage with follow-up care. Village Health Teams (VHTs) can extend this education into communities in advance of screening outreach, providing opt-out sensitization aligned with established immunization communication approaches. Care Linkage Protocols Confirmed SCD cases should be enrolled into comprehensive care within 14 days of diagnosis. The essential treatment package for confirmed HBSS disease, comprising prophylactic penicillin from two months of age, folic acid supplementation, and malaria prophylaxis, is available at national, regional, district and Health Sub-district hospitals, and has been shown to substantially reduce mortality, hospitalization, and stroke in children with SCD.30 Critically, hydroxyurea should be offered as standard of care to all patients with confirmed HbSS disease from 9 months of age, and not restricted to those with severe disease. The February 2026 launch was accompanied by a commitment from the Ministry of Health Permanent Secretary to add hydroxyurea to Uganda’s Essential Medicines List (EML), a policy shift that, if implemented, significantly strengthens the treatment case for early diagnosis.1 SMS-based appointment reminders through the existing MTRAC system (an SMS-based reporting system launched in 2011 to improve drug stock monitoring, disease outbreak response and accountability in health facilities),31 should be used to reduce loss-to-follow-up between diagnosis and treatment enrolment, leveraging a platform that is already operational across Uganda’s health facilities. DHIS2 Data Integration SCD screening data should be integrated into the existing District Health Information System 2 (DHIS2) platform, through which the Ministry of Health collects and analyses health data collected from districts. This integration enables real-time tracking of screening coverage, positivity rates, hub-level TAT, confirmatory testing completion, and loss-to-follow-up across the cascade from screening to care enrolment. A hub-level TAT dashboard would allow the programme to identify bottlenecks in sample transport or results reporting and respond before delays become systemic. DHIS2 integration avoids creating a parallel data system and leverages existing district health management infrastructure and reporting workflows as shown in Table 1. Table 1Proposed Differentiated Implementation Strategy for Universal Newborn Sickle Cell Disease Screening in UgandaComponentPrivate Sector PathwayPublic Sector PathwayCatch-Up PathwayTarget populationNewborns delivered at private and faith-based facilitiesNewborns delivered at government health facilities (HC II, III, IV, district/regional hospitalsChildren aged 1–5 years who missed screening at birth or during immunization contacts (between 0–9 months of age)Entry pointNormal delivery or delivery by cesarean sectionImmunization program contact (at 6, 10, 14 weeks, and 9 months), with 9-month contact prioritized as the most reliable screening timepoint given the HbF decline trajectorySchool-based screening and community outreach programsScreening technologyThe microchip electrophoresis analyzerSickle SCAN or HemotypeSC (Lateral flow immunoassay)Sickle SCAN or HemotypeSC (Lateral flow immunoassay)Test locationLaboratoryImmunization stationImmunization stationCost integrationIncorporated into the delivery package cost: $161–$322 for normal deliveries and $538–$1,344 for cesarean deliverySupplied through Joint medical stores/National Medical stores, free of charge at the point of serviceSupplied through Joint medical stores/National Medical stores, free of charge at the point of serviceCurrent screening cost$14–$21 when requested separatelyNot routinely availableNot routinely availableResult TAT20 minutes (Including specimen processing time)15 minutes (Negative samples including specimen processing time)2–4 days (For suspected disease or carrier status)15 minutes (Negative samples including specimen processing time)2–4 days (For suspected disease or carrier status)Confirmatory strategyPositive/ambiguous results sent for HPLC/IEF at reference laboratory or CPHLPositive results sent for Hub-based confirmation using the microchip electrophoresis analyzer (Within 40km radius)Positive results sent for Hub-based confirmation using the microchip electrophoresis analyzer (Within 40km radius)Counselling approachAntenatal genetic counselling + immediate posttest counselling with resultsAntenatal genetic counselling + pre-test education at immunization visits + immediate posttest counselling at immunization visitsPre-test education during school health programsKey advantageImmediate result while the family is still engaged with specialized and non-specialized medical teams at the hospitalLeverages existing immunization infrastructure with wide population coverageCaptures missed children, uses established outreach mechanisms (taking advantage of village health teams (VHTs))Main challengeCost barrier if not integrated into delivery package cost that would perpetuate equity concernsMultiple contacts needed with potential for loss to follow-upIdentifying and reaching missed children, late diagnosisInfrastructure requirementsThe microchip electrophoresis analyzer, 0–50µL pipette, 100–1000µL pipetteSickle SCAN kits distributed through normal government supply chainSickle SCAN kits distributed through normal government supply chain, coordination with the education sectorComponentPrivate Sector PathwayPublic Sector PathwayCatch-Up PathwayQuality assuranceFacility level protocols, periodic inter-laboratory comparison using blinded samples (including comparison with HPLC and IEF)Hub supervision, CPHL oversight, VHT coordination for community mobilizationHub supervision, CPHL oversight, VHT coordination for community mobilizationEstimated annual targetApproximately 261,783 in private and not-for-private (Faith-based) facilitiesApproximately 1,815,861 million births in public facilitiesApproximately 500,000 previously unscreened childrenSustainabilitySelf-sustaining through integration with delivery package costsGovernment budget allocation through the existing immunization programGovernment budget allocation through the existing immunization programSupporting infrastructure (For all pathways)ComponentDescriptionFunction100 laboratory hubsThe microchip electrophoresis analyzer positioned to serve facilities within 40km radiusConfirmatory testing, quality assurance, reduced TATCentral public health laboratoriesNational reference laboratory with IEF capacityComplex case confirmation, quality control oversight, national data repository, training and technical supportAntenatal care integrationGenetic counselling at all ANC contactsPrepare families for screening, provide SCD education, reduce anxiety, improve consent ratesNational data system (DHIS2)Centralized database leveraging existing data uploading mechanisms by the district biostatisticiansTrack screening coverage, monitor outcomes, ensure follow-up, support program evaluation and researchComprehensive care centersDesignated SCD treatment clinics at district/regional and national hospitals with clear referral-up pathwaysLong term care for all confirmed casesNotes: The strategy proposes three complementary pathways, using different technologies and entry points appropriate to each setting’s resources and population reach. Private facilities would use the microchip electrophoresis analyzer to provide immediate results before discharge, with screening costs incorporated into the standard delivery package costs to remove financial barriers. Public facilities would integrate Sickle SCAN testing into the established immunization program, leveraging existing infrastructure and multiple contacts during the first 9 months of age. School-based and community catch-up programs would identify previously unscreened children aged 1–5 years. All pathways would utilize the existing network of 100 hubs positions within 40km of health facilities for confirmatory testing. Complex or ambiguous cases would be referred to CPHL for IEF testing. The microchip electrophoresis analyser ambiguous/uncertain results requiring CPHL referral include: (1) samples where HbA cannot be clearly distinguished from HbF (reported as “β-thal major not ruled out”), (2) samples where HbA2 cannot be accurately measured (reported as “β-thal trait status not known; retest recommended” with A2 at 0%), (3) samples with co-migration of HbA2/C/E preventing precise A2 measurement when C or E is present, and (4) newborn samples with inconclusive patterns where SCD-SS or β-thalassemia cannot be definitively ruled out. The microchip electrophoresis analyzer cannot test for beta thalassemia in children under 6 months due to high fetal hemoglobin levels and has reduced accuracy in preterm infants born before 37 weeks gestation.Abbreviations: ANC, antenatal care; CPHL, Central Public Health Laboratories; HC, Health Center; IEF, isoelectric focusing; SCD, sickle cell disease. Table 1Proposed Differentiated Implementation Strategy for Universal Newborn Sickle Cell Disease Screening in UgandaComponentPrivate Sector PathwayPublic Sector PathwayCatch-Up PathwayTarget populationNewborns delivered at private and faith-based facilitiesNewborns delivered at government health facilities (HC II, III, IV, district/regional hospitalsChildren aged 1–5 years who missed screening at birth or during immunization contacts (between 0–9 months of age)Entry pointNormal delivery or delivery by cesarean sectionImmunization program contact (at 6, 10, 14 weeks, and 9 months), with 9-month contact prioritized as the most reliable screening timepoint given the HbF decline trajectorySchool-based screening and community outreach programsScreening technologyThe microchip electrophoresis analyzerSickle SCAN or HemotypeSC (Lateral flow immunoassay)Sickle SCAN or HemotypeSC (Lateral flow immunoassay)Test locationLaboratoryImmunization stationImmunization stationCost integrationIncorporated into the delivery package cost: $161–$322 for normal deliveries and $538–$1,344 for cesarean deliverySupplied through Joint medical stores/National Medical stores, free of charge at the point of serviceSupplied through Joint medical stores/National Medical stores, free of charge at the point of serviceCurrent screening cost$14–$21 when requested separatelyNot routinely availableNot routinely availableResult TAT20 minutes (Including specimen processing time)15 minutes (Negative samples including specimen processing time)2–4 days (For suspected disease or carrier status)15 minutes (Negative samples including specimen processing time)2–4 days (For suspected disease or carrier status)Confirmatory strategyPositive/ambiguous results sent for HPLC/IEF at reference laboratory or CPHLPositive results sent for Hub-based confirmation using the microchip electrophoresis analyzer (Within 40km radius)Positive results sent for Hub-based confirmation using the microchip electrophoresis analyzer (Within 40km radius)Counselling approachAntenatal genetic counselling + immediate posttest counselling with resultsAntenatal genetic counselling + pre-test education at immunization visits + immediate posttest counselling at immunization visitsPre-test education during school health programsKey advantageImmediate result while the family is still engaged with specialized and non-specialized medical teams at the hospitalLeverages existing immunization infrastructure with wide population coverageCaptures missed children, uses established outreach mechanisms (taking advantage of village health teams (VHTs))Main challengeCost barrier if not integrated into delivery package cost that would perpetuate equity concernsMultiple contacts needed with potential for loss to follow-upIdentifying and reaching missed children, late diagnosisInfrastructure requirementsThe microchip electrophoresis analyzer, 0–50µL pipette, 100–1000µL pipetteSickle SCAN kits distributed through normal government supply chainSickle SCAN kits distributed through normal government supply chain, coordination with the education sectorComponentPrivate Sector PathwayPublic Sector PathwayCatch-Up PathwayQuality assuranceFacility level protocols, periodic inter-laboratory comparison using blinded samples (including comparison with HPLC and IEF)Hub supervision, CPHL oversight, VHT coordination for community mobilizationHub supervision, CPHL oversight, VHT coordination for community mobilizationEstimated annual targetApproximately 261,783 in private and not-for-private (Faith-based) facilitiesApproximately 1,815,861 million births in public facilitiesApproximately 500,000 previously unscreened childrenSustainabilitySelf-sustaining through integration with delivery package costsGovernment budget allocation through the existing immunization programGovernment budget allocation through the existing immunization programSupporting infrastructure (For all pathways)ComponentDescriptionFunction100 laboratory hubsThe microchip electrophoresis analyzer positioned to serve facilities within 40km radiusConfirmatory testing, quality assurance, reduced TATCentral public health laboratoriesNational reference laboratory with IEF capacityComplex case confirmation, quality control oversight, national data repository, training and technical supportAntenatal care integrationGenetic counselling at all ANC contactsPrepare families for screening, provide SCD education, reduce anxiety, improve consent ratesNational data system (DHIS2)Centralized database leveraging existing data uploading mechanisms by the district biostatisticiansTrack screening coverage, monitor outcomes, ensure follow-up, support program evaluation and researchComprehensive care centersDesignated SCD treatment clinics at district/regional and national hospitals with clear referral-up pathwaysLong term care for all confirmed casesNotes: The strategy proposes three complementary pathways, using different technologies and entry points appropriate to each setting’s resources and population reach. Private facilities would use the microchip electrophoresis analyzer to provide immediate results before discharge, with screening costs incorporated into the standard delivery package costs to remove financial barriers. Public facilities would integrate Sickle SCAN testing into the established immunization program, leveraging existing infrastructure and multiple contacts during the first 9 months of age. School-based and community catch-up programs would identify previously unscreened children aged 1–5 years. All pathways would utilize the existing network of 100 hubs positions within 40km of health facilities for confirmatory testing. Complex or ambiguous cases would be referred to CPHL for IEF testing. The microchip electrophoresis analyser ambiguous/uncertain results requiring CPHL referral include: (1) samples where HbA cannot be clearly distinguished from HbF (reported as “β-thal major not ruled out”), (2) samples where HbA2 cannot be accurately measured (reported as “β-thal trait status not known; retest recommended” with A2 at 0%), (3) samples with co-migration of HbA2/C/E preventing precise A2 measurement when C or E is present, and (4) newborn samples with inconclusive patterns where SCD-SS or β-thalassemia cannot be definitively ruled out. The microchip electrophoresis analyzer cannot test for beta thalassemia in children under 6 months due to high fetal hemoglobin levels and has reduced accuracy in preterm infants born before 37 weeks gestation.Abbreviations: ANC, antenatal care; CPHL, Central Public Health Laboratories; HC, Health Center; IEF, isoelectric focusing; SCD, sickle cell disease. Proposed Differentiated Implementation Strategy for Universal Newborn Sickle Cell Disease Screening in Uganda Notes: The strategy proposes three complementary pathways, using different technologies and entry points appropriate to each setting’s resources and population reach. Private facilities would use the microchip electrophoresis analyzer to provide immediate results before discharge, with screening costs incorporated into the standard delivery package costs to remove financial barriers. Public facilities would integrate Sickle SCAN testing into the established immunization program, leveraging existing infrastructure and multiple contacts during the first 9 months of age. School-based and community catch-up programs would identify previously unscreened children aged 1–5 years. All pathways would utilize the existing network of 100 hubs positions within 40km of health facilities for confirmatory testing. Complex or ambiguous cases would be referred to CPHL for IEF testing. The microchip electrophoresis analyser ambiguous/uncertain results requiring CPHL referral include: (1) samples where HbA cannot be clearly distinguished from HbF (reported as “β-thal major not ruled out”), (2) samples where HbA2 cannot be accurately measured (reported as “β-thal trait status not known; retest recommended” with A2 at 0%), (3) samples with co-migration of HbA2/C/E preventing precise A2 measurement when C or E is present, and (4) newborn samples with inconclusive patterns where SCD-SS or β-thalassemia cannot be definitively ruled out. The microchip electrophoresis analyzer cannot test for beta thalassemia in children under 6 months due to high fetal hemoglobin levels and has reduced accuracy in preterm infants born before 37 weeks gestation. Abbreviations: ANC, antenatal care; CPHL, Central Public Health Laboratories; HC, Health Center; IEF, isoelectric focusing; SCD, sickle cell disease. Economic Feasibility The economic feasibility of the differentiated screening framework was estimated using Uganda-specific cost and demographic data (Supplementary File 1). In the public sector immunization-linked pathway, all children receive an initial point-of-care screening test (Sickle SCAN or HemotypeSC), with confirmatory testing using the microchip electrophoresis analyzer platform performed only for those who screen positive (approximately 13.3% based on national prevalence.7 Under this two-step approach, the estimated total cost per child screened ranges from $6.50 to $9.10, inclusive of operational and programme overheads. At this unit cost, achieving universal coverage of approximately 2.08 million children annually through public facilities would require $13.5 to $18.9 million per financial year, representing 1.2–1.7% of Uganda’s total health budget of $1.13 billion.32 This estimate excludes the one-time capital investment required to deploy the microchip electrophoresis analyzer devices across 100-laboratory hubs (approximately $337,000), which constitutes programme’s primary upfront cost and would require dedicated government or partner financing. In private facilities, screening is modelled as a single-step approach in which all newborns are tested using the microchip electrophoresis analyzer at a cost of $14–$21 per test. These costs can be absorbed within existing delivery package fees ($161–$1,344), eliminating point-of-care charges that currently limit uptake while preserving facility revenues. The overall economic case is further strengthened by the downstream cost saving from early diagnosis, as prophylactic penicillin and hydroxyurea initiated in infancy are substantially cheaper than managing advanced complications such as recurrent vaso-occlusive crises, acute chest syndrome, stroke, and repeated hospitalization in undiagnosed children. Challenges, Ethics and Equity Any population screening program must satisfy established screening criteria. SCD clearly meets the Wilson and Jungner’s principles33 in Uganda’s context, given the substantial disease burden, reliable and affordable screening tests, and effective treatments. Gene and stem cell therapy, available in limited capacity at the Joint Clinical Research Center (JCRC), represents an emerging option but it is not the primary justification for population-level screening in Uganda’s current resource context. Potential harms require explicit mitigation. False positive result causes parental anxiety and risks stigmatization of children and families. False negative, on the other hand, risks delayed diagnosis, missed prophylaxis, and preventable deaths. Robust confirmatory testing protocols for all POC-positive results, mandatory quality assurance at screening sites, accessible genetic counselling, and rapid TAT from screening to confirmed result are the primary mitigation measures. Healthcare workers at all levels of the pathway require training not only in performing the test but in communicating results sensitively and accurately, and in referring families without creating stigma. The differentiated framework does create a tiered system. Private facility newborns receive immediate electrophoresis results at discharge, while public facility newborns screened through immunization pathway wait 48–72 hours for hub confirmation of positive results. This is a translational arrangement driven by the reality that microchip electrophoresis analyzers cannot yet be placed at every public health facility. The 48–72 hours hub TAT is, however, a substantial improvement over the current 4–6 week CPHL TAT, and the longer-term trajectory of the program should be toward point-of-care confirmation at facility level as device costs decline and coverage expands. Conclusion Uganda’s February 2026 mandatory screening launch marks the translation of a decade of evidence into national policy, a milestone that few sub-Saharan African countries have achieved. The differentiated implementation framework presented is designed to address what the launch itself has not yet resolved: how to extend reliable, timely screening beyond the delivery room to the immunization platform, the school setting, and the communities where the most vulnerable children live. The framework’s core logic of matching technology to care-entry point and age-group, anchoring confirmation in the 100-laboratory hubs network, and routing supplies through existing JMS and NMS channels, is grounded in ten years of Uganda’s program data and validated by the operational decisions already made at the February 2026 launch. In our view, the most urgent implementation priorities are: decentralizing electrophoretic or HPLC-based confirmation to laboratory hubs to reduce TAT from weeks to 48–72 hours, ensuring hydroxyurea is available as standard of care at regional, district and health sub-district following its addition to the EML, and developing the immunization-linked and community-based pathways to close the coverage gaps for children missed at birth. The question is no longer whether Uganda can afford to screen. The policy decision has been made. The economic case for hub-level confirmatory testing is further strengthened by the fact that, despite specificities generally exceeding 98–99%, point-of-care lateral flow immunoassays may still generate occasional false-positive or phenotype misclassification results under field conditions. Confirmatory testing is therefore essential before enrolment into lifelong SCD care to avoid unnecessary treatment and follow-up. The question is whether the implementation infrastructure, confirmatory testing capacity, treatment access, and data systems can be built and sustained at the pace that Uganda’s 20,000 annual SCD births demand.